



September 29, 2017

AGTC to Present at Upcoming Gene Therapy Conferences

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 29, 2017 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases, today announced that management will be participating in the following conferences:

- ▮ **Alliance for Regenerative Medicine (ARM)'s Cell & Gene Meeting on the Mesa — La Jolla, Calif. (October 4-6, 2017)**
AGTC President & CEO Sue Washer will deliver a company presentation at 11:15am PT on October 4. Ms. Washer will also moderate a panel discussion titled "Gene Therapy: Building the Gene Medicine Pipeline Through Next Generation Technologies" at 4:00pm PT the same day.
- ▮ **Chardan Gene Therapy Conference — New York (October 10, 2017)**
Ms. Washer will participate in an analyst-led fireside chat at 3:15pm ET. A live audio webcast of the presentation will be accessible by visiting ir.agtc.com/events.cfm. A replay will be available on the company's website following the event. Ms. Washer will also participate in a panel discussion titled "Gene Therapies: Pricing and Other Commercial Considerations" at 4:15pm ET.

About AGTC

AGTC is a clinical-stage biotechnology company that uses a proprietary gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. Its initial focus is in the field of ophthalmology, where it has active clinical trials in X-linked retinoschisis (XLRS), X-linked retinitis pigmentosa (XLRP), and achromatopsia (ACHM CNGB3 & ACHM CNGA3). In addition to its clinical trials, AGTC has preclinical programs in optogenetics, adrenoleukodystrophy (ALD), which is a disease of the central nervous system (CNS), and otology. The clinical-stage XLRS and XLRP programs, the discovery program in ALD and two additional ophthalmology programs are being developed in collaboration with Biogen. In addition to its product pipeline, AGTC has a significant intellectual property portfolio and extensive expertise in the design of gene therapy products including capsids, promoters and expression cassettes, as well as expertise in the formulation, manufacture and physical delivery of gene therapy products.

IR/PR CONTACTS:

David Carey (IR) or Tom Vickery (PR)
Lazar Partners Ltd.
T: (212) 867-1768 or (646) 871-8482
dcarey@lazarpartners.com or tvickery@lazarpartners.com

CORPORATE CONTACTS:

Bill Sullivan
Chief Financial Officer
Applied Genetic Technologies Corporation
T: (617) 843-5728
bsullivan@agtc.com

Stephen Potter
Chief Business Officer
Applied Genetic Technologies Corporation
T: (617) 413-2754
spotter@agtc.com